Global Gastric Volvulus Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Gastric Volvulus Treatment Market Size

• The global gastric volvulus treatment market size was valued at USD 28.23 billion in 2024 and is expected to reach USD 40.45 billion by 2032, at a CAGR of 4.6% during the forecast period
• The market growth is largely fueled by increasing awareness of gastric volvulus as a critical gastrointestinal condition and advancements in minimally invasive surgical techniques and treatment options
• Furthermore, rising demand for early diagnosis, effective intervention methods, and integrated care pathways in both hospital and outpatient settings is positioning advanced gastric volvulus treatment solutions as the preferred choice among healthcare providers. These converging factors are accelerating the adoption of innovative treatment approaches, thereby significantly boosting the industry’s growth

Gastric Volvulus Treatment Market Analysis

• Gastric volvulus treatment refers to the medical and surgical interventions aimed at correcting the abnormal twisting of the stomach (volvulus) and preventing its recurrence. The primary goals of treatment are to relieve the obstruction, restore normal blood flow to the stomach, and prevent complications such as ischemia, necrosis, and perforation
• The escalating demand for advanced treatment options is primarily fueled by increasing diagnosis rates, rising awareness about gastric volvulus complications, and technological advancements in minimally invasive procedures
• North America dominates the gastric volvulus treatment market with the largest revenue share of 43.6% in 2024, characterized by high healthcare expenditure, advanced medical infrastructure, and a strong presence of key players offering innovative surgical and endoscopic solutions
• Asia-Pacific is expected to be the fastest-growing region in the gastric volvulus treatment market during the forecast period due to increasing healthcare infrastructure development, rising awareness, and growing patient populations in countries such as China and India
• Surgery segment dominates the gastric volvulus treatment market with a share of 79.8% in 2024, driven by its high success rates and preference among healthcare providers for definitively treating acute and chronic cases, alongside the growing adoption of minimally invasive laparoscopic techniques

Report Scope and Gastric Volvulus Treatment Market Segmentation      

Gastric Volvulus Treatment Market Trends

“Technological Advancements Enhancing Treatment and Patient Care”

• A significant and accelerating trend in the global gastric volvulus treatment market is the integration of advanced technologies that enhance patient care, monitoring, and treatment management. AI-driven diagnostic tools and voice-activated healthcare applications are improving treatment precision and patient convenience
  • For instance, AI-powered diagnostic platforms are being used to detect gastric volvulus symptoms earlier and more accurately, while voice-enabled apps assist patients in managing their treatment schedules and post-operative care instructions. Similarly, telemedicine solutions incorporating voice recognition help streamline consultations and follow-ups for gastric volvulus patients
• AI integration enables predictive analytics that can assess patient risk factors and suggest personalized treatment plans, improving clinical outcomes. Voice control features support hands-free patient interaction with healthcare systems, facilitating ease of use, especially for elderly or mobility-impaired individuals
• The seamless integration of these technologies with electronic health records (EHR) and smart medical devices allows centralized monitoring and management of gastric volvulus cases, enhancing coordination between patients, caregivers, and healthcare providers
• This move towards intelligent, patient-centric treatment solutions is reshaping expectations in gastric volvulus care. As a result, companies and healthcare providers are investing in AI-enabled diagnostic tools and voice-integrated patient support systems to offer improved treatment experiences
• The demand for technologically advanced gastric volvulus treatment solutions is rapidly growing across hospitals, specialty clinics, and homecare settings, driven by the increasing focus on personalized medicine and remote patient management

Gastric Volvulus Treatment Market Dynamics

Driver

“Growing Need Due to Rising Prevalence and Advancements in Diagnostic Techniques”

• The rising incidence of gastric volvulus, particularly among geriatric populations and patients with underlying anatomical abnormalities, is driving demand for prompt and effective treatment options
  • For instance, in March 2024, the Mayo Clinic launched a study aimed at improving early diagnosis of gastric volvulus using high-resolution imaging, signaling increased clinical focus on this condition. Such initiatives support the growth of the gastric volvulus treatment market during the forecast period
• As awareness increases among clinicians and patients about the critical nature of early intervention, there is a growing emphasis on faster diagnosis and minimally invasive surgical solutions to reduce complications and hospital stay durations
• Furthermore, advancements in radiologic imaging, such as CT and MRI, have significantly enhanced the detection rate of gastric volvulus, allowing for quicker treatment decisions and better patient outcomes
• The integration of diagnostic tools into emergency and gastroenterology departments, coupled with growing healthcare infrastructure in emerging markets, is also contributing to increased treatment access. These developments support the expanding adoption of surgical and non-surgical interventions in both developed and developing healthcare settings

Restraint/Challenge

“Limited Awareness and High Risk of Misdiagnosis”

• One of the major challenges facing the gastric volvulus treatment market is the limited awareness of the condition among both patients and healthcare providers, particularly in rural and underdeveloped areas. The rarity and nonspecific symptoms of gastric volvulus often lead to misdiagnosis or delayed diagnosis
  • For instance, studies published in 2023 by the Journal of Gastrointestinal Surgery reported that misdiagnosis remains a leading contributor to complications such as gastric necrosis and volvulus recurrence
• Due to a lack of training or exposure, primary care physicians and emergency medical staff may fail to identify gastric volvulus promptly, leading to increased patient morbidity and longer hospital stays
• Moreover, advanced imaging techniques needed for accurate diagnosis may not be readily available in low-resource settings, which limits early intervention opportunities. The technical expertise required for surgical intervention, particularly laparoscopic procedures, further compounds access challenges in some regions
• Addressing these issues through increased clinical training, awareness campaigns, and investment in diagnostic infrastructure will be critical to improving detection and treatment outcomes and thereby supporting long-term market growth

Gastric Volvulus Treatment Market Scope

The market is segmented on the basis of type, treatment type, drug class, route of administration, end-user, and distribution channel.

• By Type

On the basis of type, the gastric volvulus treatment market is segmented into organo-axial volvulus and mesentero-axial volvulus. The organo-axial volvulus segment dominated the market with the largest revenue share of 61.3% in 2024, attributed to its higher prevalence, especially in elderly patients and those with diaphragmatic defects. This type is more frequently diagnosed in clinical settings and often requires surgical intervention due to its recurrent nature.

The mesentero-axial volvulus segment is projected to witness the fastest CAGR of 7.8% during the forecast period, driven by growing awareness, advancements in imaging techniques, and the increasing accuracy of diagnosis among healthcare professionals.

• By Treatment Type

On the basis of treatment type, the gastric volvulus treatment market is segmented into medication and surgery. The surgery segment accounted for the largest revenue share of 79.8% in 2024, owing to its definitive treatment approach for both acute and chronic gastric volvulus cases. Minimally invasive laparoscopic procedures are gaining preference due to shorter hospital stays and faster recovery times.

The medication segment is expected to witness the fastest CAGR from 2025 to 2032, primarily for non-emergency management and as adjunct therapy to reduce symptoms such as nausea and abdominal pain.

• By Drug Class

On the basis of drug class, the gastric volvulus treatment market is segmented into analgesics, antiemetic agents, and others. The antiemetic agents segment held the largest share of 48.9% in 2024, due to their widespread use in managing nausea and vomiting, which are primary symptoms of gastric volvulus.

The analgesics segment is projected to grow at a significant CAGR of 6.3% from 2025 to 2032, driven by the need for pain relief in both preoperative and postoperative care.

• By Route of Administration

On the basis of route of administration, the gastric volvulus treatment market is segmented into oral and parenteral. The parenteral segment dominated the market with a revenue share of 57.6% in 2024, as intravenous administration is preferred in emergency care settings for rapid drug action.

The oral segment is expected to witness the fastest CAGR from 2025 to 2032 due to its use in outpatient settings and for patients in stable condition or under symptom management plans.

• By End-User

On the basis of end-user, the market is segmented into hospitals, homecare, specialty clinics, and others. The hospitals segment held the largest market share of 66.5% in 2024, due to the availability of surgical equipment, emergency services, and specialized care required for managing acute gastric volvulus cases.

The homecare segment is expected to witness the fastest growth at a CAGR of 8.1%, fueled by post-surgical care, ongoing symptom management, and increased preference for home-based recovery supported by healthcare professionals.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into hospital pharmacy and retail pharmacy. The hospital pharmacy segment held the largest market share of 63.7% in 2024, supported by direct in-hospital treatment and the immediate need for medications and surgical tools in emergency settings.

The retail pharmacy segment is projected to grow at a notable CAGR from 2025 to 2032, driven by rising patient discharges and follow-up treatments requiring medication from external sources, especially antiemetics and pain relievers.

Gastric Volvulus Treatment Market Regional Analysis

• North America dominates the gastric volvulus treatment market with the largest revenue share of 43.6% in 2024, driven by the region's advanced healthcare infrastructure, higher awareness of gastrointestinal disorders, and greater accessibility to diagnostic imaging and surgical interventions
• Patients and healthcare providers in the region prioritize timely diagnosis and treatment of gastric volvulus, supported by strong clinical guidelines and the availability of minimally invasive surgical procedures in both public and private healthcare settings
• This regional dominance is further supported by higher healthcare expenditure, an aging population more prone to gastric motility disorders, and an increasing focus on improving patient outcomes through early intervention and advanced therapeutic options

U.S. gastric volvulus treatment market insight

The U.S. gastric volvulus treatment market captured the largest revenue share in 2024 within North America, driven by advanced diagnostic capabilities, widespread availability of emergency surgical care, and high awareness levels among both patients and healthcare providers. The presence of leading gastrointestinal surgeons and specialized hospitals, along with a growing number of gastrointestinal disorders, continues to support strong market demand.

Europe gastric volvulus treatment market insight

The Europe gastric volvulus treatment market is expected to grow at a CAGR of 7.9% from 2025 to 2032, fueled by a rising elderly population, improved access to emergency care, and expanding healthcare infrastructure. Countries such as Germany, the U.K., and France are witnessing growing adoption of laparoscopic procedures and early diagnostic interventions. Strict clinical protocols and rising healthcare funding are also playing pivotal roles in driving market expansion.

U.K. gastric volvulus treatment market insight

The U.K. gastric volvulus treatment market is projected to grow at a CAGR of 6.8% during the forecast period, supported by increasing demand for minimally invasive procedures and the rising burden of age-related gastric disorders. Growing public-private partnerships and NHS efforts to reduce emergency care delays are boosting early diagnosis and prompt surgical intervention rates.

Germany gastric volvulus treatment market insight

The Germany gastric volvulus treatment market is forecasted to grow at a CAGR of 7.2%, driven by advanced medical technology adoption and strong institutional focus on gastrointestinal care. Germany’s emphasis on training, clinical trials, and endoscopic surgery contributes to high treatment success rates and patient outcomes, further enhancing market credibility.

Asia-Pacific gastric volvulus treatment market insight

The Asia-Pacific gastric volvulus treatment market is poised to grow at the fastest CAGR of 19.4% from 2025 to 2032, supported by rising healthcare expenditures, increasing urbanization, and growing awareness of gastrointestinal disorders. Governments across the region are expanding healthcare access and investing in endoscopy and surgical infrastructure, making treatment more accessible in both urban and rural areas.

China gastric volvulus treatment market insight

The China gastric volvulus treatment market accounted for the largest revenue share in Asia-Pacific in 2024, driven by increasing cases of digestive and motility disorders, high urban population density, and better access to tertiary care hospitals. Local manufacturing capabilities and government initiatives supporting surgical equipment and emergency care are fueling domestic availability and adoption of gastric volvulus treatment procedures.

Japan gastric volvulus treatment market insight

The Japan gastric volvulus treatment market is growing steadily due to the country’s aging population, high medical literacy, and emphasis on technological innovation. The market benefits from widespread use of endoscopic diagnostics and strong demand for less invasive surgical techniques. Growing hospital investments in robotics and advanced surgical platforms also contribute to positive patient outcomes and procedure efficiency.

Gastric Volvulus Treatment Market Share

The gastric volvulus treatment industry is primarily led by well-established companies, including:

• Sawai Pharmaceutical Co., Ltd (Japan)
• PAI Pharma (U.S.)
• Sun Pharmaceutical Industries Ltd (India)
• ANI Pharmaceuticals, Inc. (U.S.)
• Fresenius SE & Co. KGaA (Germany)
• Mayne Pharma Group Limited (Australia)
• Teva Pharmaceutical Industries Ltd (Israel)
• GLENMARK PHARMACEUTICALS LTD. (India)
• Tris Pharma, Inc. (U.S.)
• Pfizer, Inc. (U.S.)
• Mallinckrodt (U.K.)
• Viatris Inc. (U.S.)
• GSK plc (U.K.)  
• Vintage Labs (India)
• Zydus Group (India)

SKU-46429